Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

LENZ Therapeutics (LENZ) Shares Outstanding (Diluted Average) (2022 - 2025)

LENZ Therapeutics (LENZ) has disclosed Shares Outstanding (Diluted Average) for 4 consecutive years, with $28.8 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 35.39% to $28.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28.8 million through Dec 2025, up 35.39% year-over-year, with the annual reading at $28.8 million for FY2025, 35.39% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $28.8 million at LENZ Therapeutics, up from $28.5 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $55.2 million in Q3 2022, with the low at $2.0 million in Q1 2023.
  • Average Shares Outstanding (Diluted Average) over 4 years is $27.8 million, with a median of $27.5 million recorded in 2025.
  • The sharpest move saw Shares Outstanding (Diluted Average) tumbled 96.46% in 2023, then skyrocketed 1288.98% in 2024.
  • Over 4 years, Shares Outstanding (Diluted Average) stood at $54.9 million in 2022, then crashed by 96.43% to $2.0 million in 2023, then soared by 987.83% to $21.3 million in 2024, then skyrocketed by 35.39% to $28.8 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $28.8 million, $28.5 million, and $28.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.